Compare OXLC & VOGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OXLC | VOGX |
|---|---|---|
| Founded | 2010 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.0M | 482.8M |
| IPO Year | 2010 | 2026 |
| Metric | OXLC | VOGX |
|---|---|---|
| Price | $4.92 | $12.55 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 2.3M | 81.7K |
| Earning Date | 11-01-2023 | 11-06-2026 |
| Dividend Yield | ★ 18.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $136.15 | N/A |
| Revenue Next Year | $5.51 | N/A |
| P/E Ratio | $7.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.62 | $11.51 |
| 52 Week High | $15.39 | $38.41 |
| Indicator | OXLC | VOGX |
|---|---|---|
| Relative Strength Index (RSI) | 20.13 | 33.36 |
| Support Level | $4.62 | N/A |
| Resistance Level | $10.10 | $22.10 |
| Average True Range (ATR) | 0.26 | 2.36 |
| MACD | 0.02 | -0.61 |
| Stochastic Oscillator | 16.14 | 11.58 |
Oxford Lane Capital Corp is a non-diversified closed-end management investment company. The fund's investment objective is to maximize portfolio's risk adjusted total return, and currently seek to achieve investment objective by investing in structured finance investments, specifically the equity and junior debt tranches of CLO vehicles, which are collateralized by a diverse portfolio of senior secured loans made to companies whose debt is unrated or is rated below investment grade (the Senior Loans) and, to a limited. Its investment plan also includes investing in warehouse facilities, which are financing structures intended to aggregate senior loans that may be used to form the basis of a CLO vehicle.
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.